VolitionRx Limited (NYSE American: VNRX) announced the successful validation and verification of the chemiluminescent immunoassay (CLIA) version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan. The transition from manual plates to automated processing on the IDS i10 automated analyzer platform is expected to support faster turnaround times and higher throughput as demand increases. With more than 1,700 veterinary hospitals in Japan already registered to use the test, the automation milestone is a critical step in scaling the test's availability.
Japan's pet dog population is approximately seven million, according to Volition. The automated platform aligns with the same system used for the company's human Nu.Q Cancer, Nu.Q NETs, and Nu.Q Discover products, highlighting cross-platform synergy. This integration allows Volition to leverage existing infrastructure and expertise across both human and animal health applications.
The Nu.Q Vet Cancer Test is a blood-based assay that detects nucleosomes associated with cancer, enabling early detection and monitoring of the disease in dogs. By automating the test on the IDS i10 platform, Volition aims to provide veterinary clinics with faster results, which is crucial for timely treatment decisions. The company noted that the automation validation in Japan represents a significant commercial milestone, as it moves the test from a manual process to a scalable, high-throughput solution suitable for central laboratories.
Volition is focused on advancing the science of epigenetics for earlier detection and monitoring of life-altering diseases in both humans and animals. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information, visit the company's website at https://volition.com/.
The successful validation in Japan underscores Volition's commitment to expanding its veterinary diagnostics portfolio and addressing the growing demand for non-invasive cancer detection tools in pets. As the company continues to automate its testing platforms, it positions itself to capture a larger share of the veterinary diagnostic market.
